6
A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients With Intermediate or High-Risk Primary or Secondary Myelofibrosis
Clinical Trials AK
Preface
1
Introduction
2
ETCHEM10675
3
ABNL-MARRO
4
ABNL-MARRO Arm A
5
ABNL-MARRO Arm B
6
A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients With Intermediate or High-Risk Primary or Secondary Myelofibrosis
7
INCB160058-101 trial HEM 24055
8
HEM 24599_Elritercept
9
Weekly low-dose regimen of decitabine and venetoclax
10
AU-018 Clinical Trial
11
Summary
References
Table of contents
6.1
Nuvisertib Monotherapy Arm 1
6.2
Nuvisertib Add-on to Ruxolitinib Arm 2
6.3
Nuvisertib and Momelotinib Combination Arm 3
6
A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients With Intermediate or High-Risk Primary or Secondary Myelofibrosis
6.1
Nuvisertib Monotherapy Arm 1
6.2
Nuvisertib Add-on to Ruxolitinib Arm 2
6.3
Nuvisertib and Momelotinib Combination Arm 3
5
ABNL-MARRO Arm B
7
INCB160058-101 trial HEM 24055